Cipla Welcomes Abraxane ANDA Approval After Tackling Goa Compliance Issues

Only Second Abraxane ANDA And Fourth ‘Therapeutic Equivalent’ To BMS Brand

 
• By Dean Rudge

Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.

• Source: Shutterstock

More from Generics

More from Business